WHO classification recognizes grade II astrocytomas, oligodendrogliomas and oligoastrocytomas. Conventional MRI is used for differential diagnosis, guiding surgery, planning radiotherapy and monitoring treatment response. Advanced imaging techniques can increase the diagnostic accuracy. Younger age, normal neurological examination, oligodendroglial histology and 1p loss are favorable prognostic factors. Prophylactic antiepileptic drugs are not useful, whilst there is no evidence that one drug is better than the others. Total/near total resection can improve seizure control, progression-free and overall survival, whilst reducing the risk of malignant transformation. Early post-operative radiotherapy improves progression-free but not overall survival. Low doses of radiation are as effective as high doses and better tolerated. Modern radiotherapy techniques reduce the risk of late cognitive deficits. Chemotherapy can be useful both at recurrence after radiotherapy and as initial treatment after surgery to delay the risk of late neurotoxicity from large-field radiotherapy. Neurocognitive deficits are frequent and can be caused by the tumor itself, tumor-related epilepsy, treatments and psychological distress.

Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force.

SOFFIETTI, Riccardo;
2010-01-01

Abstract

WHO classification recognizes grade II astrocytomas, oligodendrogliomas and oligoastrocytomas. Conventional MRI is used for differential diagnosis, guiding surgery, planning radiotherapy and monitoring treatment response. Advanced imaging techniques can increase the diagnostic accuracy. Younger age, normal neurological examination, oligodendroglial histology and 1p loss are favorable prognostic factors. Prophylactic antiepileptic drugs are not useful, whilst there is no evidence that one drug is better than the others. Total/near total resection can improve seizure control, progression-free and overall survival, whilst reducing the risk of malignant transformation. Early post-operative radiotherapy improves progression-free but not overall survival. Low doses of radiation are as effective as high doses and better tolerated. Modern radiotherapy techniques reduce the risk of late cognitive deficits. Chemotherapy can be useful both at recurrence after radiotherapy and as initial treatment after surgery to delay the risk of late neurotoxicity from large-field radiotherapy. Neurocognitive deficits are frequent and can be caused by the tumor itself, tumor-related epilepsy, treatments and psychological distress.
2010
17
1124
1133
Advisory Committees; trends, Antineoplastic Protocols; standards, Cognition Disorders; drug therapy/etiology/surgery, Combined Modality Therapy; methods/standards, Europe, Evidence-Based Medicine; trends, Glioma; radiotherapy/surgery/therapy, Humans, Neoplasm Metastasis; diagnosis/drug therapy/radiotherapy, Neoplasm Recurrence; Local; drug therapy/radiotherapy/surgery, Neurosurgical Procedures; methods/standards, Prognosis
R. Soffietti;B. G. Baumert;L. Bello;A. v. Deimling;H. Duffau;M. Frénay;W. Grisold;R. Grant;F. Graus;K. Hoang-Xuan;M. Klein;B. Melin;J. Rees;T. Siegal;A. Smits;R. Stupp;W. Wick;E. F. of
File in questo prodotto:
File Dimensione Formato  
Soffietti_et_al-2010-European_Journal_of_Neurology.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 122.99 kB
Formato Adobe PDF
122.99 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/121624
Citazioni
  • ???jsp.display-item.citation.pmc??? 126
  • Scopus 415
  • ???jsp.display-item.citation.isi??? 356
social impact